Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068649 · ClinicalTrials.gov registry record · Phase 2
Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer
A Phase 2 study of Metastatic Malignant Neoplasm, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,500
- Enrollment target
- 3
- Study locations
NCT04068649 is a Phase 2 study of Metastatic Malignant Neoplasm that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 1,500 participants, above the 238-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (530% higher). The trial reports 3 study locations across 1 state.
The verdict
NCT04068649, a Phase 2 study of Metastatic Malignant Neoplasm, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,500 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies how well single-fraction stereotactic body radiation therapy (SBRT) works when compared to standard radiation therapy in treating patients with cancer that has spread to other places in the body (metastatic). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- RADIATION Stereotactic Body Radiation Therapy
- OTHER Questionnaire Administration
- RADIATION Palliative Radiation Therapy
Study Locations (3)
New York
- Roswell Park Cancer Institute - Buffalo
- The Cancer Institute at St. Francis Hospital - East Hills
- Good Samaritan Hospital - West Islip
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2027-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04068649
The ClinicalTrials.gov registry entry for NCT04068649 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 238-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (530% higher). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Malignant Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04068649 reports 3 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04068649 about?
NCT04068649 is a clinical study titled "Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer". This phase II trial studies how well single-fraction stereotactic body radiation therapy (SBRT) works when compared to standard radiation therapy in treating patients with cancer that has spread to other places in the body (metastatic). Stereotactic body radiation therapy uses special equipment to p...
What is the current status of trial NCT04068649?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,500 participants. The study started on 2019-11-18. Estimated completion is 2027-11-18.
What conditions does trial NCT04068649 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm.
What interventions are being tested in trial NCT04068649?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Stereotactic Body Radiation Therapy (RADIATION), Questionnaire Administration (OTHER), Palliative Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04068649?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04068649 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
ACTIVE NOT RECRUITING · Phase 2
-
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.